Levonorgestrel Intrauterine System For Emergency Contraception

NCT01539720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2024-02-20

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse.

While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.

Conditions

  • Pregnancy, Unplanned
  • Pregnancy; Accident

Interventions

DRUG

Ulipristal acetate

30 mg tablet

DEVICE

levonorgestrel IUS

Levonorgestrel IUS, 52mg placed intrauterine

Sponsors & Collaborators

  • William and Flora Hewlett Foundation

    collaborator OTHER
  • University of Colorado, Denver

    collaborator OTHER
  • Planned Parenthood Federation of America

    collaborator OTHER
  • University of Rochester

    collaborator OTHER
  • Planned Parenthood of the St. Louis Region and Southwest Missouri

    lead OTHER

Principal Investigators

  • Colleen McNicholas, DO, MCSI · Planned Parenthood of the St. Louis Region and Southwest Missouri

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539720 on ClinicalTrials.gov